Share of Clicks for top 10 US Pharma & Biotech Research and Development brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| lilly.com | 40.38 |
| regeneron.com | 5.59 |
| abbvie.com | 4.83 |
| gsk.com | 4.21 |
| ro.co | 3.95 |
| merck.com | 3.14 |
| roche.com | 2.49 |
| ziphealth.co | 2.14 |
| ubrelvyhcp.com | 2.04 |
| novonordisk-us.com | 2.01 |
| others | 29.22 |
- lilly.com - 40.38%
- regeneron.com - 5.59%
- abbvie.com - 4.83%
- gsk.com - 4.21%
- ro.co - 3.95%
- merck.com - 3.14%
- roche.com - 2.49%
- ziphealth.co - 2.14%
- ubrelvyhcp.com - 2.04%
- novonordisk-us.com - 2.01%
- others - 29.22%
Copyright © Adthena. All rights reserved.
In the PPC landscape, lilly.com dominates with 40.38% click share, while ‘others’ collectively hold 29.22%, showcasing diverse competition.
Share of Spend for the top 10 US Pharma & Biotech Research and Development brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | lilly.com | ro.co | novonordisk-us.com | ziphealth.co | pfizerforall.com | scemblix.com | ubrelvyhcp.com | evenity.com | hims.com | regeneron.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/08/01 | 37.23% | 9.48% | 2.2% | 4.53% | 3.85% | 1.04% | 0.17% | 4.07% | 2.39% | 1.38% |
| 2026/08/02 | 44.92% | 5.16% | 0.92% | 2.3% | 3.45% | 1.27% | 0.52% | 4% | 1.91% | 1.14% |
| 2026/08/03 | 36.78% | 6.02% | 4.04% | 1.9% | 5.31% | 1.29% | 0.59% | 4.96% | 1.36% | 1.92% |
| 2026/08/04 | 35.16% | 9.07% | 3.54% | 2.61% | 4.46% | 1.38% | 0.22% | 2.96% | 2.29% | 1.12% |
| 2026/08/05 | 37.55% | 6.28% | 2.9% | 1.97% | 5.4% | 1.73% | 2.03% | 1.27% | 1.39% | 0.78% |
| 2026/08/06 | 41.59% | 7.12% | 4% | 2.32% | 1.42% | 1.59% | 2.15% | 4.18% | 1.1% | 0.74% |
| 2026/08/07 | 41.31% | 7.16% | 1.49% | 1.72% | 4.92% | 2.11% | 2.02% | 2.06% | 0.94% | 1.52% |
| 2026/08/08 | 42.82% | 7.3% | 5.83% | 1.71% | 1.98% | 1.88% | 1.83% | 1.96% | 1.49% | 0.62% |
| 2026/08/09 | 45.13% | 2.54% | 5.56% | 0.43% | 0.56% | 2.08% | 2.01% | 4.59% | 0.04% | 2.4% |
| 2026/08/10 | 40.05% | 5.8% | 4.23% | 1.65% | 3.07% | 1.68% | 1.31% | 5.2% | 0.06% | 2.52% |
| 2026/08/11 | 37.01% | 5.39% | 3.99% | 3.22% | 2.04% | 1.89% | 2.89% | 2.94% | 1.88% | 1.88% |
| 2026/08/12 | 34.16% | 6.4% | 4.13% | 2.77% | 3.87% | 1.65% | 2.34% | 4.58% | 2.04% | 0.97% |
| 2026/08/13 | 32.89% | 6.38% | 4.98% | 4.22% | 3.87% | 1.52% | 3.48% | 5.22% | 2.53% | 1.69% |
| 2026/08/14 | 34.69% | 5.6% | 4.95% | 3.47% | 2.66% | 1.92% | 3.53% | 2.62% | 1.46% | 1.78% |
| 2026/08/15 | 36.64% | 7.64% | 3.08% | 3.45% | 2.61% | 1.68% | 2.28% | 5.06% | 1.58% | 1.42% |
| 2026/08/16 | 39.43% | 7.42% | 1.05% | 3.76% | 1.4% | 1.91% | 2.63% | 2.56% | 2.06% | 1.76% |
| 2026/08/17 | 41.83% | 6.77% | 1.56% | 2.16% | 1.2% | 1.59% | 3.42% | 3.43% | 1.66% | 3.22% |
| 2026/08/18 | 40.43% | 6.48% | 1.15% | 3.49% | 1.22% | 2.09% | 3.24% | 3.76% | 2.75% | 1.68% |
| 2026/08/19 | 37.87% | 11.69% | 1.26% | 2.85% | 1.34% | 2.08% | 1.65% | 4% | 1.36% | 1.52% |
| 2026/08/20 | 36.71% | 6.9% | 3.47% | 3.25% | 1.55% | 1.71% | 2.31% | 5.03% | 3.54% | 1.94% |
| 2026/08/21 | 37.29% | 8.4% | 3.47% | 4.7% | 2.24% | 1.2% | 2.01% | 3.78% | 0.65% | 1.03% |
| 2026/08/22 | 40.09% | 5.84% | 3.96% | 3.69% | 2.59% | 1.1% | 2.66% | 2.88% | 2.21% | 1.42% |
| 2026/08/23 | 39.43% | 7.48% | 2.96% | 1.96% | 2.8% | 1.89% | 2.01% | 2.91% | 1.3% | 2.7% |
| 2026/08/24 | 40.65% | 6.66% | 2.86% | 3.32% | 2.45% | 1.82% | 1.91% | 2.08% | 0.89% | 2.4% |
| 2026/08/25 | 39.04% | 8.62% | 4.22% | 2.52% | 2.11% | 1.56% | 2.6% | 1.67% | 0.63% | 1.08% |
| 2026/08/26 | 40.42% | 9.22% | 4.13% | 2.45% | 2.24% | 1.24% | 1.58% | 1.91% | 1.39% | 1.08% |
| 2026/08/27 | 41.41% | 7.68% | 4.65% | 2.21% | 2.76% | 1.39% | 2.4% | 2.04% | 0.72% | 1.47% |
| 2026/08/28 | 40.78% | 7.93% | 5.26% | 2.13% | 3.22% | 1.4% | 2.14% | 1.95% | 0.99% | 0.99% |
| 2026/08/29 | 41.34% | 4.7% | 5.3% | 1.44% | 2.38% | 2.11% | 2.35% | 1.33% | 0.92% | 1.48% |
| 2026/08/30 | 43.2% | 5.77% | 4.97% | 2.11% | 1.92% | 1.77% | 1.99% | 1.13% | 0.84% | 0.68% |
| 2026/08/31 | 43.43% | 4.56% | 3.96% | 3.57% | 2.35% | 1.98% | 1.79% | 1.69% | 1.13% | 0.51% |
- lilly.com
- ro.co
- novonordisk-us.com
- ziphealth.co
- pfizerforall.com
- scemblix.com
- ubrelvyhcp.com
- evenity.com
- hims.com
- regeneron.com
Copyright © Adthena. All rights reserved.
Lilly.com led August with fluctuating spend, peaking at 45.13% on the 9th. Ro.co saw a notable dip mid-month, while Novo Nordisk’s share remained steady. By month’s end, Lilly.com maintained dominance at 43.43%.
Competitor Count for US Pharma & Biotech Research and Development
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/08/01 | 454 |
| 2026/08/02 | 461 |
| 2026/08/03 | 463 |
| 2026/08/04 | 477 |
| 2026/08/05 | 400 |
| 2026/08/06 | 390 |
| 2026/08/07 | 375 |
| 2026/08/08 | 360 |
| 2026/08/09 | 363 |
| 2026/08/10 | 387 |
| 2026/08/11 | 402 |
| 2026/08/12 | 410 |
| 2026/08/13 | 398 |
| 2026/08/14 | 381 |
| 2026/08/15 | 378 |
| 2026/08/16 | 374 |
| 2026/08/17 | 380 |
| 2026/08/18 | 379 |
| 2026/08/19 | 358 |
| 2026/08/20 | 369 |
| 2026/08/21 | 375 |
| 2026/08/22 | 366 |
| 2026/08/23 | 356 |
| 2026/08/24 | 359 |
| 2026/08/25 | 356 |
| 2026/08/26 | 359 |
| 2026/08/27 | 352 |
| 2026/08/28 | 359 |
| 2026/08/29 | 358 |
| 2026/08/30 | 367 |
| 2026/08/31 | 365 |
Copyright © Adthena. All rights reserved.
August began with 454 advertisers, peaking at 477 on the 4th. A decline followed, reaching 352 on the 27th. The month concluded with 365 advertisers.
